Neurodegeneration – News and Features

The Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for Pelizaeus-Merzbacher Disease.

The funds will be used for constructing a headquarters for the program to enhance scientists’ efforts to develop treatments for a wide range of diseases.

Teva to finance Jexys' R&D program for the development of a high throughput drug discovery platform and in return will receive a minority equity interest in Jexys.

Researchers have identified a potential target for developing novel therapeutics for intervention in AD.

AFFiRiS starts pre-clinical development of its first Parkinson's vaccine that will be investigated for efficacy in Parkinson models.

A study at the Salk Institute confirmed that dysfunctional human astrocytes turn against their charges and kill off healthy motor neurons.

Einstein researchers clarify how two major variants of HIV differ in their ability to cause neurologic complications.

Neutekbio's technologies and products complement Biomonitor’s current offerings for treatment of patients with Multiple Sclerosis, Rheumatoid Arthritis and Crohn’s disease.

Company advance to Phase II of its SBIR grant “Intrathecal Cyclosporin for the Treatment of Amyotrophic Lateral Sclerosis.”

The collaboration aims to advance development of Neuralstem's human spinal cord neural stem cell therapies.